Is methicillin-resistant *Staphylococcus aureus* a common pathogen in ventilation-associated pneumonia? The experience of a tertiary teaching hospital in Jordan

Ziad A. Elnasser, MD, PhD\*\textsuperscript{a,b}; Haneen M. Obeidat, Master’s Degree\textsuperscript{b}; Mo’ath E. Bani-Salem, Bachelor’s Degree\textsuperscript{c}; Zouhair O. Amarin, PhD\textsuperscript{d}; Ali F. Banni-Issa, Bachelor’s Degree\textsuperscript{e}; Nasser M. Kaplan, PhD\textsuperscript{a}

**Abstract**

Ventilator-associated pneumonia is a life threatening device related infection in intensive care units. Methicillin-resistant *Staphylococcus aureus* is considered a common contagious pathogen causing pneumonia and sepsis.

To assess the prevalence of *S aureus* in comparison to other pathogens, and their antibacterial sensitivity profile in ventilator-associated pneumonia.

Data regarding ventilator-associated pneumonia of adults admitted to the intensive care unit, at the Jordan University of Science and Technology Hospital, between 2012 and 2018 were extracted from the computerized system. Microorganisms and their susceptibility profiles were identified according to the Clinical and Laboratory Standards Institute.

There were 547 isolates, of which 35 (6.4%) were Gram positive, 59% were methicillin resistant. Gram-negative isolates were present in 507 (92.6%) isolates, of which 82% were multidrug resistant, and 1% were Candida species.

Gram-negative bacterial infections were significantly associated with ventilation usage. *S aureus* was not the predominant pathogen.

**Abbreviations:** A baumannii = Acinetobacter baumannii, ICU = intensive care unit, K pneumoniae = Klebsiella pneumoniae, MDR = multidrug resistance, MRSA = methicillin-resistant Staphylococcus aureus, P aeruginosa = Pseudomonas aeruginosa, *S aureus* = Staphylococcus aureus, VAP = ventilator-associated pneumonia, XDR = extensively drug resistance.

**Keywords:** extensively drug resistance, methicillin resistance, multidrug resistance, *Staphylococcus aureus*, ventilator-associated pneumonia

1. Introduction

*Staphylococcus aureus* (*S aureus*) is a common pathogen in humans.\textsuperscript{[1,2]} This gram-positive organism, mainly found in elderly patients, is often virulent and resistant to therapy, resulting in an increased risk of co-morbidities.\textsuperscript{[2,3]}

From hundreds of its various strains, Methicillin-resistant *S aureus* (MRSA) was defined in 1961.\textsuperscript{[4]} It is considered a severe contagious pathogen causing skin infections, pneumonia, bacteremia, and other pathologies at healthcare facilities.\textsuperscript{[5,6]}

Patients with poor glucose control are quite susceptible to MRSA infection, being an independent risk factor for mortality.\textsuperscript{[7]}

Approximately 10% of ventilation cases are associated with *S aureus* infection, with a death rate of around 50%. Device-associated infections in intensive care units (ICUs) are reported to increase the risk to health worldwide.\textsuperscript{[8]}

According to a study by the World Health Organization covering low and middle income countries, the rate of ventilator-associated pneumonia (VAP) was 23.9 per 1000 ventilator days.\textsuperscript{[9]} Globally, the resistance phenomenon for both MRSA and gram-negative bacteria has been noted to be on the rise.\textsuperscript{[10,11]}

The objectives of this study were to estimate the rate of MRSA and other pathogens in relation to mechanical ventilation, antimicrobial resistance, length of hospital stay, and mortality at the ICU of the Jordan University of Science and Technology Hospital.
2. Methods

This study was conducted at a tertiary-care referral hospital that is affiliated to the Jordan University of Science and Technology, and serves 1.2 million people. The ICU consists of 6 units, each with its designated beds. A medical unit with 16 beds, a surgical unit with 12 beds, a coronary care unit with 12 beds, a cardiac unit with 6 beds, a neurological surgery unit with 6 beds, and a burn unit with 2 beds. Data were obtained from the electronic database system.

This retrospective study included all patients admitted to ICU with VAP between January 2012 and December 2018. The isolates were obtained from sputum, broncho-alveolar lavage, and bronchial washings associated with ventilator usage.

In addition to age and gender, patients’ details included the co-morbidities of diabetes mellitus, hypertension, chronic obstructive pulmonary disease, chronic heart failure, chronic renal failure, different malignancies, respiratory distress syndrome, antimicrobial susceptibility, length of hospital, and ICU stay and outcome.

Specimens were cultured on chocolate, blood, and MacConkey agar according to the Clinical and Laboratory Standards Institute and the European Committee on Antimicrobial Susceptibility Testing guidelines.[12] For the purposes of this study, MRSA implied resistance against oxacillin. Multidrug resistance (MDR) was defined as antimicrobial resistance shown by a species of microorganism to at least 1 antimicrobial drug in 3 or more antimicrobial categories. Extensively drug resistance (XDR) implied that isolates were susceptible to 1 or 2 antimicrobial categories, and pan drug resistance implied that isolates were resistant to all antimicrobial categories.[14] Ventilator utilization ratio referred to the number of ventilation days per number of patient days, and VAP related to 1000 ventilation days.

The study was approved by the Institutional Research Board of the Jordan University of Science and Technology.

Statistical analysis was performed using the Statistical Package for Social Sciences (Windows 22.0, SPSS Inc.). Quantitative data were expressed as means and standard deviations. Two tail independent samples were used for comparisons, and qualitative data as percentages. Chi-squared test was used for comparison at independent samples were used for comparisons, and qualitative were expressed as means and standard deviations. Two tail for Social Sciences (Windows 22.0, SPSS Inc.). Quantitative data

Regarding the distribution of 547 cases of VAP, 254 patients were affected by 1 type of bacteria, and 92 patients were affected by more than 1 type of bacteria. Both gram-positive and gram-negative bacteria were isolated. Nonfermenting gram-negative bacteria were common. Acinetobacter baumannii (A baumannii) was the predominant agent at 59%, followed by Pseudomonas aeruginosa (P aeruginosa) at 17.9%. S aureus was recovered in 6.2% with a methicillin resistance rate of 58.8% (Table 2).

Regarding resistance to antibiotics, A baumannii isolates had the highest rates of resistance to different antibiotic classes, where 82% were XDR, while 22.4% of P aeruginosa was XDR, and 38.9% of Klebsiella pneumoniae (K pneumoniae) were MDR. Regarding S aureus isolates, 64.7% were MDR (Table 3). The incidence of VAP was 17.2/1000 ventilation days. Ventilator utilization ratio was 0.43 and the ventilator days were 2854 (Table 4).

3. Results

During the study period, 11,850 patients were admitted to the ICU for a cumulative number of 46,865 days, and 19,724 intubation device days. A total of 346 patients developed VAP. The mean age was 56.7 ± 20 years, and 63.6% were male. S aureus was reported in 20 (5.8%) patients. The total hospital length of stay including ICU was 49.3 days. Co-morbidities of diabetes mellitus were present in 38.7%, hypertension in 51.4%, and cardiac disease in 29.8%.

By comparing risk factors for VAP between the MRSA group and the non-MRSA group, there was no statistically significant difference in relation to age and co-morbidities. On the other hand, gender, length of hospital stay, mortality rate, and super-infections were significantly different, where the number of males was higher in MRSA group (P =.011). The mortality rate and super infections were higher in the non-MRSA group (P =.007 and .003, respectively) (Table 1).

### Table 1
General characteristics of patients with ventilator associated pneumonia and methicillin resistant Staphylococcus aureus (MRSA) status.

|                        | MRSA (n = 20) | Non MRSA (n = 326) | Total (n = 346) | P-value |
|------------------------|--------------|--------------------|----------------|---------|
| Age (yr, mean ± SD)    | 52.4 ± 21.9  | 56.9 ± 20.3        | 56.7 ± 20.4    | .330    |
| Gender M N (%)         | 18 (90)      | 202 (62)           | 220 (63.6)     | .011    |
| HLOS (d, mean ± SD)    | 77.5 ± 81.9  | 47.5 ± 49.7        | 49.3 ± 52.4    | .013    |
| Co-morbidities         | 17           | 294                | 311            | .44     |
| DM                     | 6 (30.3)     | 128 (39.3)         | 134 (38.7)     | .409    |
| Cardiac diseases       | 9 (45)       | 94 (28.8)          | 103 (29.8)     | .125    |
| Brain diseases         | 8 (40)       | 109 (33.4)         | 117 (33.8)     | .547    |
| Lung diseases          | 2 (10)       | 54 (16.6)          | 56 (16.2)      | .539    |
| Kidney diseases        | 2 (10)       | 32 (9.8)           | 34 (9.8)       | .979    |
| Malignancies           | 3 (15)       | 45 (13.8)          | 48 (13.9)      | .881    |
| Mortality (%)          | 11 (55.0%)   | 262 (80.4%)        | 273 (78.9%)    | .007    |
| Super infections (%)   | 13 (65)      | 290 (90.5)         | 303 (89)       | .003    |

DM = diabetes mellitus, HLOS = hospital length of stay, HTN = hypertension.

### Table 2
The isolated microorganisms from the target population.

| Microorganism species | Total number of isolates (N) | Resistance prevalence (%) | Resistant codes N (%) |
|-----------------------|-----------------------------|---------------------------|-----------------------|
| S aureus              | 34 (6.2)                    | 58.8                      | MRSA                  |
| P aeruginosa          | 98 (17.9)                   | 44.9                      | MDR                   |
| K pneumonia           | 54 (9.9)                    | 42.5                      | MDR                   |
| E coli                | 15 (2.7)                    | 86.7                      | MDR                   |
| A Baumannii           | 323 (59.0)                  | 99.7                      | MDR                   |
| P mirabilis           | 4 (0.7)                     | 100                       | MDR                   |
| S pneumonia           | 1 (0.2)                     | 0                         | N/A                   |
| S maltophilia         | 3 (0.5)                     | 100                       | MDR                   |
| M morganii            | 1 (0.2)                     | 100                       | MDR                   |
| S marcescens          | 2 (0.4)                     | 100                       | N/A                   |
| Koari                 | 1 (0.2)                     | 0                         | N/A                   |
| E cloacae             | 3 (0.5)                     | 33.3                      | N/A                   |
| Junii                 | 1 (0.2)                     | 100                       | MDR                   |
| H parainfluenza       | 1 (0.2)                     | 0                         | N/A                   |
| Albicans              | 4 (0.7)                     | 0                         | N/A                   |
| Burkholderia cepacia  | 1 (0.2)                     | 100                       | MDR                   |
| Krusei                | 1 (0.2)                     | 0                         | N/A                   |

MDR = multidrug resistant, MRSA = methicillin resistant Staphylococcus aureus, N/A = nonapplicable.
4. Discussion

In this study, gram-negative bacteria were identified in more than 90% of the isolates. This may be explained by an increased resistance, or may be associated with infection prevention practices against gram-positive bacteria. A baumannii, P aeruginosa, K pneumonia, and S aureus were the dominant pathogens in patients with pneumonia. This is similar to a Polish study, where A baumannii, P aeruginosa, S aureus, and K pneumonia were the dominant pathogens, albeit at different percentages. A baumannii was classiﬁed as a frequent cause of nosocomial infection worldwide. This is in concordance with the findings of this study, where A baumannii was a common causative pathogen of pneumonia in the ICU. S aureus was reported as the fourth most frequent pathogen at 6.2%. This is in contrast to its prevalence in the United States, at 20%, and its prevalence in Asian countries where it occupies a third position.

Recently, A baumannii was classiﬁed as a frequent cause of nosocomial infection worldwide. This is in contrast to its prevalence in the United States, at 20%, and its prevalence in Asian countries where it occupies a third position.

Table 3

| Antibiotics names (%) | A baumannii N = 323 | P aeruginosa N = 98 | K pneumonia N = 54 | S aureus N = 34 |
|-----------------------|---------------------|---------------------|---------------------|-----------------|
| Aminoglycosides       |                     |                     |                     |                 |
| Amikacin              | 12.7                | 22.4                | 1.9                 | –               |
| Gentamycin            | 71.8                | 44.9                | 9.3                 | 20.6            |
| Tobramycin            | 45.8                | 40.8                | 5.6                 | 2.9             |
| Carbapenems           |                     |                     |                     |                 |
| Imipenem              | 66.9                | 31.6                | 27.8                | –               |
| Meropenem             | 59.1                | 56.1                | 16.7                | –               |
| Cephalosporins        |                     |                     |                     |                 |
| Ceftazidime           | 60.1                | 34.7                | 14.8                | –               |
| Cefepime              | 99.4                | 31.6                | 74.1                | –               |
| Ceftriaxone           | 43.3                | 7.1                 | 68.5                | 5.9             |
| Cefoxime              | 36.8                | 5.2                 | 66.7                | –               |
| Ceftolin              | 0.6                 | –                   | 1.9                 | 55.9            |
| Fluoroquinolones      |                     |                     |                     |                 |
| Ciproﬂoxacin         | 61.1                | 35.5                | 9.3                 | 17.6            |
| Levoﬂoxacin          | 29.4                | 5.1                 | 14.8                | 2.9             |
| Penicillins           |                     |                     |                     |                 |
| Piperacillin          | 84.2                | 38.8                | 40.7                | 2.9             |
| Oxacillin             | 15.2                | 14.3                | –                   | 58.8            |
| Penicillins and B inhibitors |             |                     |                     |                 |
| Ticarcillin/clavulanic acid | 7.4                | 23.5                | 3.7                 | –               |
| Piperacillin/tazobactam | 37.8              | 17.3                | 3.7                 | –               |
| Ampicillin/sulbactam  | 71.1                | 2.2                 | 18.5                | –               |
| Polymyxins            |                     |                     |                     |                 |
| Colistin              | –                   | –                   | –                   | –               |
| Lacosamide            | –                   | –                   | –                   | –               |
| Clindamycin           | –                   | –                   | –                   | 32.4            |
| Oxazolidinone         |                     |                     |                     |                 |
| Linezolid             | 43.3                | 29.6                | 7.4                 | 2.9             |
| Tetracyclines         |                     |                     |                     |                 |
| Doxycycline           | –                   | –                   | –                   | 0               |
| Minocycline           | 41.2                | 30.6                | 40.7                | 0               |
| Macrolide             |                     |                     |                     |                 |
| Erythromycin          | –                   | –                   | –                   | 14.7            |
| Glycopeptide          |                     |                     |                     |                 |
| Vancomycin            | –                   | –                   | –                   | 0               |
| Teicoplanin           | 11.1                | –                   | 3.7                 | 14.7            |
| Antimicins            |                     |                     |                     |                 |
| Rifampin              | –                   | –                   | –                   | 0               |
| Type of resistance (%)|                     |                     |                     |                 |
| MDR                   | 17.7                | 22.4                | 38.9                | 64.7            |
| XDR                   | 82                  | 22.4                | 3.7                 | 0               |
| PDR                   | 0                   | 0                   | 0                   | 0               |
| MRSA                  | –                   | –                   | –                   | 58.8            |

MDR = multidrug resistant, MRSA = methicillin resistant Staphylococcus aureus, PDR = pan drug resistant, XDR = extensively drug resistant, – = not tested.
rates were 80% to imipenem, 78.2% to ceftazidime, and 75.9% to ampicillin and sulbactam.\[20]\n
Regarding *P. aeruginosa*, the resistance to meropenem was 56.1%, gentamicyn 44.9%, and ceftazidime 34.7%. This is in contrast to an Indian study, where the resistance to cefepime was 79.2%, ceftazidime 68.5%, and gentamicyn 71.4%.\[21]\n
In relation to *K. pneumoniae*, 68.5% of strains were extended spectrum beta lactamase. This is in contrast to that reported at 35.1% and 19.5% in Europe and the United States respectively.\[22]\n
The incidence of VAP was 17.2/1000 patient ventilation days. This is much higher than those reported by neighboring and some other far away countries in which the incidence varied between 0.9 and 13.1/1000 days.\[23]\n
In a systematic review of device-associated, hospital-acquired infections in developed versus developing countries, the incidence rates were 9.6 and 21.4, respectively.\[24]\n
### 5. Conclusion

Device-associated infections in ICUs are common, with an emergence of extra resistance organisms. Gram-negative bacterial infections are significantly associated with ventilation usage. *S. aureus* is not the predominant pathogen.

### Acknowledgments

The authors thank the infection control unit for their contribution in data collection.

### Author contributions

Conceptualization: Ziad A. Elnasser, Haneen M. Obeidat.

Data curation: Haneen M. Obeidat, Mo’ath E. Bani-Salem.

Formal analysis: Haneen M. Obeidat.

Funding acquisition: Ziad A. Elnasser.

Investigation: Ziad A. Elnasser, Haneen M. Obeidat.

Methodology: Mo’ath E. Bani-Salem.

Project administration: Ziad A. Elnasser, Haneen M. Obeidat.

Resources: Ali F. Banni-Issa.

Software: Mo’ath E. Bani-Salem, Ali F. Banni-Issa.

Supervision: Ziad A. Elnasser.

Validation: Ziad A. Elnasser, Haneen M. Obeidat, Zouhair O. Amarin, Nasser M. Kaplan.

Visualization: Ziad A. Elnasser, Zouhair O. Amarin.

Writing -- original draft: Ziad A. Elnasser, Haneen M. Obeidat.

Writing -- review & editing: Ziad A. Elnasser, Haneen M. Obeidat, Zouhair O. Amarin.

### References

[1] Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998;339:520–32.

[2] Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev 2015;28:603–61.

[3] Bouza E, Giannella M, Bunsow E, et al. Ventilator-associated pneumonia due to meticillin-resistant Staphylococcus aureus: risk factors and outcome in a large general hospital. J Hosp Infect 2012;80:150–5.

[4] Combes A, Luyt CE, Fagon JY, et al. Impact of meticillin resistance on outcome of Staphylococcus aureus ventilator-associated pneumonia. Am J Respir Crit Care Med 2004;170:786–92.

[5] Bronwasser S. Comparability of antimicrobial susceptibility test results from 22 European countries and Israel: an external quality assurance exercise of the European Antimicrobial Resistance Surveillance System (EARSS) in collaboration with the United Kingdom National External Quality Assurance Scheme (UK NEQAS). J Antimicrob Chemother 2002;50:953–64.

[6] Athanassia Z, Sipmos II, Falagas ME. Impact of meticillin resistance on mortality in Staphylococcus aureus VAP: a systematic review. Eur Respir J 2008;31:625–32.

[7] Zhang Q, Chen H, Liu B, Zhou M. Methicillin-resistant Staphylococcus aureus pneumonia in diabetics: a single-center, retrospective analysis. Chin Med J 2019;132:1429.

[8] Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet Lond Engl 2002;359:753–9.

[9] World Health Organization (2010). The Burden of Health Care-associated Infection Worldwide. Available at: http://www.who.int/gpsc/country_work/burden_hcai/en [access date September 2014].

[10] Livermore DM. Fourteen years in resistance. Int J Antimicrob Agents 2012;39:283–94.

[11] Menichetti F, Tagliabue E. Antimicrobial resistance in internal medicine wards. Intern Emerg Med 2012;3:S271–81.

[12] Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. An Informational Supplement for Global Application Developed through the Clinical and Laboratory Standards Institute. 2011;33.

[13] Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268–81.

[14] Macvane SH. Antimicrobial resistance in the intensive care unit. J Intensive Care Med 2017;32:25–37.

[15] Kolpa M, Walaszek Z, Gnadek A, Wolak Z, Dobroś W. Incidence, microbiological profile and risk factors of healthcare-associated infections in intensive care units: a 10-year observation in a provincial hospital in Southern Poland. Int J Environ Res Public Health 2018;15:112.

[16] Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008;21:538–82.

[17] Rubinstein E, Kollef MH, Narwhani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008;46 (Supplement_5):S378–85.

[18] Hidron AI, Edwards JR, Patel J, et al. Participating National Healthcare Safety Network Facilities/Amicrobial-resistant pathogens associated with health-care-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008;29:996–1011.

[19] Huang L, Zhang R, Hu Y, et al. Epidemiology and risk factors of methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci infections in Zhejiang China from 2015 to 2017. Antimicrob Resist Infect Control 2019;8:90.

[20] Chung DR, Song JH, Kim SH, et al. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med 2011;184:1409–17.

[21] Gupta R, Malik A, Rizvi M, Ahmed M, Singh A. Epidemiology of multidrug-resistant Gram-negative pathogens isolated from ventilator-associated pneumonia in ICU patients. J Glob Antimicrob Resist 2017;5:47–50.

[22] Luyt CE, Hékimian G, Koulenti D, Chastre J. Microbial cause of ICU-acquired pneumonia: hospital-acquired pneumonia versus ventilator-associated pneumonia. Curr Opin Crit Care 2018;24:332–8.

[23] Resenthal VD, Al-Abdely HM, El-Kholy AA, et al. International nosocomial infection control consortium report, data summary of 50 countries for 2010-2015: device-associated module. Am J Infect Control 2017;45:1495–504.

[24] Pettemerides Y, Vasilios R. Incidence rate of device-associated, hospital acquired infections in ICUs: a systematic review developed versus developing economies. Int J Caring Sci 2018;11:1913.